Equity Profile

JNJ

Johnson & Johnson

Health CarePharmaceuticals$632.4B

Jul15Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Johnson & Johnson (JNJ) is a leading health care company known for its pharmaceuticals, medical devices, and consumer health products. With a market cap of $632 billion, it plays a significant role in the health care sector, impacting everything from medications to personal care items.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$2.84

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$25.0B

Wall Street expectations, options signals, track record, and call prep available with Pro.

JNJ Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.82%

Avg Stock Reaction

+1.22%

Last Quarter Recap

In Q1 2026, Johnson & Johnson reported an EPS of $2.70, beating estimates by 1.09%. The stock reacted positively, gaining 0.90% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Johnson & Johnson to report solid earnings this quarter, with a consensus EPS of $2.84 and revenue of $25.0 billion. The company's strong history of beating EPS estimates adds to the optimistic outlook.

Bull Case

If Johnson & Johnson exceeds the EPS estimate, it could signal strong demand for its products and effective cost management, potentially leading to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations, it may raise concerns about its growth prospects and market competition, resulting in a negative stock reaction.

Key Metrics to Watch

Earnings Per Share (EPS)

$2.84

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$25.0B

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Johnson & Johnson's EPS exceed the consensus estimate of $2.84?

A beat on EPS would reinforce investor confidence in the company's growth and operational efficiency.

What insights will management provide regarding revenue growth and product demand?

Understanding revenue drivers is crucial for assessing the company's market position and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the impact of recent product launches, which could drive higher-than-expected revenue growth this quarter.

Supporting Evidence

Johnson & Johnson has consistently beaten EPS estimates in recent quarters, suggesting strong operational execution.

The options market is pricing a larger move than historical averages, indicating potential for a significant reaction.

Key Risk

If revenue growth comes in below $24.6 billion, it could challenge the bullish consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will reflect the company's ability to navigate market challenges and maintain growth.

Bull Confirmed If

An EPS of $2.90 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $2.70 would raise concerns about demand and profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±7.37%

Historical Avg

±1.9%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating uncertainty around the earnings report.

Options are pricing ±7.4% while JNJ has averaged ±1.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

19.7%

Calls (398K)P/C Ratio: 0.92Puts (415K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Johnson & Johnson beats expectations, history suggests a positive stock reaction of around +1.22%, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline, with historical patterns indicating a potential drop of around -0.48%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·3 sells

Members

House + Senate

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

R-NJThomas H. Kean JrRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the performance of new pharmaceutical products.
2Updates on cost management strategies and their impact on margins.
3Insights into market demand trends for consumer health products.
4Management's outlook on future revenue growth and market conditions.
5Any potential changes in guidance or strategic direction.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Fastenal Company

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$2.84

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$25.0B

Wall Street expectations, options signals, track record, and call prep available with Pro.

JNJ Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.82%

Avg Stock Reaction

+1.22%

Last Quarter Recap

In Q1 2026, Johnson & Johnson reported an EPS of $2.70, beating estimates by 1.09%. The stock reacted positively, gaining 0.90% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Johnson & Johnson exceeds the EPS estimate, it could signal strong demand for its products and effective cost management, potentially leading to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations, it may raise concerns about its growth prospects and market competition, resulting in a negative stock reaction.

Key Metrics to Watch

Earnings Per Share (EPS)

$2.84

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$25.0B

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Johnson & Johnson's EPS exceed the consensus estimate of $2.84?

A beat on EPS would reinforce investor confidence in the company's growth and operational efficiency.

What insights will management provide regarding revenue growth and product demand?

Understanding revenue drivers is crucial for assessing the company's market position and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the impact of recent product launches, which could drive higher-than-expected revenue growth this quarter.

Supporting Evidence

Johnson & Johnson has consistently beaten EPS estimates in recent quarters, suggesting strong operational execution.

The options market is pricing a larger move than historical averages, indicating potential for a significant reaction.

Key Risk

If revenue growth comes in below $24.6 billion, it could challenge the bullish consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will reflect the company's ability to navigate market challenges and maintain growth.

Bull Confirmed If

An EPS of $2.90 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $2.70 would raise concerns about demand and profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±7.37%

Historical Avg

±1.9%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating uncertainty around the earnings report.

Options are pricing ±7.4% while JNJ has averaged ±1.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

19.7%

Calls (398K)P/C Ratio: 0.92Puts (415K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Johnson & Johnson beats expectations, history suggests a positive stock reaction of around +1.22%, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline, with historical patterns indicating a potential drop of around -0.48%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·3 sells

Members

House + Senate

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

R-NJThomas H. Kean JrRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the performance of new pharmaceutical products.
2Updates on cost management strategies and their impact on margins.
3Insights into market demand trends for consumer health products.
4Management's outlook on future revenue growth and market conditions.
5Any potential changes in guidance or strategic direction.